Evaluating the Efficacy and Safety of Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) causes end-stage renal disease (ESRD) and a decline in the estimated glomerular filtration rate (eGFR) (1,2). In this meta-analysis, we aimed to assess the efficacy and safety of tolvaptan in delaying both eGFR decline and total kidney...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Mohamed Ibrahim, Ibrahim Nagmeldin Hassan, Ahmed Mohammed Alhassan Ismail Abdulsamad
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	University Library System, University of Pittsburgh 2025-01-01
Цуврал:	International Journal of Medical Students
Нөхцлүүд:	Autosomal dominant polycystic kidney disease (ADPKD) Tolvaptan eGFR (estimated glomerular filtration rate) TKV (total kidney volume)
Онлайн хандалт:	http://ijms.info/IJMS/article/view/2968
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!